The Development of a Radioimmuno-Assay for Carcino-Embryonic Antigen with some Applications. Clinical Evaluation of Cercino-Ernbryonic Antigen, I by PERSIJN, J.-P. & Korsten, C. B.
Persijn and Korsten: Radioimmuno-assay for caicino-embryonic antigen in serum and urine 377
J. Clin. Chem. din. Biochem.
Vol. 14,1976, pp. 377-387
The Development of a Radioimmuno-Assay for Carcino-Embryonic Antigen with some Applications
Clinical Evaluation of Cercino-Ernbryonic Antigen, I
By J.-P. Persijn and C B. Korsten
From the Department of Clinical Chemistry (Head: Dr. J.-P. Persijn), Netherlands Cancer Institute, Amsterdam
(Received December 19, 1975/May 16, 1976)
Summary: This paper, the first in a series devoted to the study of the clinical usefulness of estimations of carcino-
embryonic antigen (CEA) in serum and urine, describes in detail a direct radioimmunoassay for CEA in serum and
urine ( a modifiedEgan technique,Egan>M. L. et al. (1972), Immunochemistry, 9, 289-299). A comparative study
of the behaviour of CEA batches and anti-CEA antisera from different laboratories in the radioimmunoassay is pre-
sented.
The incidence of increased serum CEA levels in healthy smokers was found to be related to smoking habits.
Assays of CEA in serum obtained by the direct technique and the Hansen perchloric acid — zirconyl gel technique
(Hansen, H. J. et al. (1971), Clin. Res. 79, 143-147) showed comparable results.
Various problems affecting the assay of CEA in serum and urine are critically discussed, e.g. criteria for absorbing-
out of anti-CEA antisera, identification of CEA, factors causing false CEA values, use of reference materials, accept-
ability of a strict cut-off level to indicate increased CEA levels; and factors governing the choice of antisera. In this
connection we present a new approach which maintains a reliable and consistent cut-off level in follow-up studies.
Evidence is presented that urinary CEA is heterogeneous and perchloric acid-unstable.
Entwicklung ernes Radioimmunassay für carcino-embryonales Antigen und seine Anwendung
Klinische Bedeutung des carcino-embryonalen Antigens, L Mitteilung
Zusammenfassung: Diese erste Arbeit einer Serie, die sich mit der klinischen Bedeutung der Bestimmung von „Car-
cino-embryonic antigen" (CEA) im Serum und im Urin befaßt, beschreibt eine direkte radioimmunologische Bestim-
mung für CEA im Serum und im Urin (modifiziert nzchEgan, M. L. et al. (1972), Immunochemistry, P, 289-299).
Eine Vergleichsstudie bezüglich derCEA-Präparationen und Antisera gegen CEA aus verschiedenen Laboratorien
wird beschrieben.
Es wird gezeigt, daß erhöhte CEA-Werte bei gesunden Rauchern mit den Rauchgewohnheiten zusammenhängen.
Bestimmungen von CEA im Serum mit der direkten radioimmunologischen Methode und der Perchlorsäure-Zirconyl-
gel-Technik (Hansen, H. /. et al. (1971), Clin. Res. 7P, 143-147) weisen vergleichbare Ergebnisse auf.
Kritisch besprochen werden mehrere Probleme, die mit der CEA-Bestimmung zusammenhängen, wie z. B. das
Problem der Isolierung von CEA-Antiseren durch Absorption, Charakterisierung von CEA, Faktoren, welche falsche
CEA-Werte verursachen, Gebrauch von Referenzsubstanzen, Zuverlässigkeitskriterien für einen Grenzwert zwischen
dem normalen und erhöhten CEA-Bereioh, und Faktoren, die die Wahl von Antisera bestimmen. In diesem Zusam-
menhang wird ein neues Verfahren vorgeschlagen, um mit zuverlässigen Grenzwerten während der Verlaufsstudie
arbeiten zu können. Es wird nachgewiesen, daß CEA im Urin heterogen ist und Extraktion mit Perchlorsäure zum
Verlust von nachweisbarem CEA führt.
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Introduction
Studies by Go Id & Freedman (1,2) in 1965 revealed the
presence of a tumour-associated antigen in adenocarcino-
mas of the colon as well as in foetal colonic mucosa.
This antigen was therefore named carcinoembryonic
antigen (CEA)1) of the human digestive system.
In 1969 Thomson et al. (3) introduced a radioimmuno-
assay for the measurement of a colonic tumour-asso-
ciated antigen in human sera.
The usefulness of serial measurements of CEA in
monitoring the effects of therapy and in the long term
follow-up has attracted more attention very recently.
Mach et al. pointed out that, despite the large number
of CEA tests already performed in many institutes
(4-11), very few follow-up studies have been reported
(12). A more extensive study of the value of CEA in
different body fluids for diagnosis, follow-up and
prognosis in cancer patients was started in 1973. The
generally accepted assay for CEA .is the radioimmuno-
assay (13, 14, 15). CEA is a glycoprotein soluble in
1 mol/1 perchloric acid (16).
Other perchloric acid soluble glycoproteins, like non-
specific cross reacting antigen, which have antigenic
determinants in common with CEA, have been
reported (17-22). Blood group antigens, such as A,
etc., can be associated with certain CEA preparations
(23, 24) and in consequence the antiserum may con-
tain a high titer of anti-A antibodies. Anti-A antibodies,
either from the antiserum or from the test sample, may
become attached to the labelled CEA in the assay and
thus diminish the accessibility of the anti-CEA anti-
bodies for the labelled CEA. In such cases the test
results are unreliable. If a sample contains blood group
antigen A, an interaction can take place between A,
the Α-like site on labelled CEA and anti-A antibodies
present in the anti-CEA antiserum. A radioimmuno-
assay for CEA will also measure antigen A activity and
the test result is not representative of the true CEA
content of the sample. This is accounted for in the
technology of the radioimmuno-assay used in the
clinical study in the present paper.
Materials and Methods
Reagents
Phosphate buffers
Sodium phosphate-buffered saline contained NaCl (9 g/1) and
dipotassium ethylene dinitrilotetra-acetate (0.7 mmol/1)
(K2EDTA) in phosphate buffer (0.05 mol/1). The resulting
^Abbreviations
Ace = anti-CEA antiserum prepared by Dr. Toad's group
(Duarte, USA); CEA = carcino-embryonic antigen;
CEADU = CEA prepared by Dr. Toad's group; CEAL = CEA
prepared by Dr. Mack's group (Lausanna); G-10-2 = anti-
CEA antiserum prepared by Dr. Mack's group; 6G3 = anti-
CEA antiserum prepared by Dr. Neville's group (London);
NKI-3 = anti-CEA antiserum prepared by us; 2SDI = CEA
prepared by us.
solution had a pH of 7.4. In some cases 0.5 ml rabbit serum
was added to 100 ml of this solution.
Borate buffer
Sodium borate (0.125 mol/1), pH 8.4.
Radioactive iodine (1257) was obtained from the Radio-
chemical Centre (code IMS-3Q).
Chloramine T solution
Chloramine T (Merck) was dissolved in borate b ffer (0.8 g/l).
Sodium metabisulflte solution
Sodium metabisulfite (Merck) was dissolved in borate buffer
(2.4 g/1).
Isolation of CEA
Isolation of CEA was performed, using essentially the procedure
described by Krupey et al. (25), with several modifications. The
perchloric acid extract of liver metastases from a colonic tumour
was passed through a Sepharose 4B column. Phosphate buffer
(pH 5.5) containing 1 g/1 NaNa was used for preparation of the
column and for elution. The fractions were monitored by
absorbance measurements at 280 nm and tested for the pre-
sence of CEA by the Ouchterlony technique, using anti CEA
antiserum kindly provided by Dr. S. von Kleist (Ville-juif,
France). The CE -containing fractions were pooled, lyophil-
ized and re-run oh Sepharose 4B. The CEA-containing fractions
were dialysed carefully against twice distilled water until the
Na and K contents were zero (as judged by flame-photometric
determination), then lyophilized. The CEA thus prepared, and
used in this study, is designated 2SDI.
Preparation of standards
A stock solution of about 20 mg/l was prepared in phosphate
buffered saline, containing rabbit serum and stored at - 20°C.
V/eighing was done with a Cahn microbalance. Dilutions were
made with phosphate buffered saline, containing rabbit serum, to
1000 and 750 Mg/l for the assay, in serum and to 500 and 200 Mg/i
for the assay in urine.
Labelling of CEA
CEA (about 300 Mg) was dissolved in twice distilled water (first
brought to neutrality with ammonia) to a concentration of
1 g/1. Quantities of 10 μΐ were dispensed in a number of tubes
and lyophilized. The tubes were kept at - 20°C until iodination.
The first step in the iodination procedure was the addition of
20 μΐ phosphate buffered saline to a tube brought to room
temperature.
Radioiodination of CEA, using I mCi 125I, was accomplished
by the Brown & Reith modification of the Hunter & Greenwood
procedure (26) within 2 days after receipt of 125I. The iodination
time was usually 50 seconds. The iodination reaction was stopped
by addition of 25 μΐ bisulfite solution and the mixture was trans-
ferred to a Sephadex G 25 column previously equilibrated with
phosphate buffered saline containing rabbit serum. The transfer
was facilitated by addition of 0.2 mi KI solution (carrier iodide).
The column was slowly eluted with phosphate buffered saline
and the fractions containing the highest activity were used for the
radioimmunorassay. As the labelled CEA decayed, the percentage
of labelled CEA bound by the diluted anti-CEA antisera
gradually decreased (about 10% in 3 weeks). As a rule, freshly
labelled CEA was applied every 2—3 weeks.
Anti-CEA antisera
Various goat antisera were used: NKI-3 was prepared in goats
by intramuscular injections of 100 jug 2 SDI in physiological
saline, emulsified with complete Freund's adjuvant, injections
were repeated 5 times at intervals of about 1 month. The anti-
serum with the highest titre of anti-CEA antibodies was chosen
for use in the clinical studies and was named NKI^32).
2) Small amounts of NKI-3, sufficient for 1000 assays, are
available on request.
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G-10-2 was a gift from Dr. Mach (Lausanne). It had been ab-
sorbed out with polymerized human normal serum and normal
perchloric acid extractable giycoproteins.
Antisera to goat serum
These were obtained from the Central Laboratory of the
Netherlands Blood Transfusion Service (Amsterdam).
Procedure for the radioimmuno-assay
Principles of the assay
CEA levels were estimated by the double antibody technique
ofEgan et al. (15) with several modifications.
Two assay systems have been developed: system 1 for assay of
CEA in serum, system 2 for CEA measurements in urine.
Radioimmuno-assay in serum (system 1)
Plastic tubes (size 4 cm, i.d. 8 mm with round bottom) were
used for the assay. An amount of 200 μΐ of the patient's serum
was mixed with 50 μΐ goat antiserum to CEA diluted with
phosphate buffered saline containing rabbit serum, and 20 μΐ
phosphate buffered saline containing rabbit serum. For NKI-3
a dilution 1:12.000 was generally used. Incubation was per-
formed overnight in a water bath at 37°C; 50 μΐ (1251)CEA
(3 Mg/lXwere added to each tube and incubation was then
continued for two hours. Separation of antibody*-bound CEA
was performed as described under "Separation of antibody-
bound CEA from unbound CEA". For the construction of the
standard inhibition curve serial two-fold dilutions (with phos-
phate buffered saline containing rabbit serum) were prepared
from two different CEA stock solutions containing 1000 and
750 Mg/1 CEA in phosphate buffered saline containing rabbit
serum, respectively, to obtain more points for the construction
of the standard inhibition curve. The procedure as described
above was followed with two modifications: 200 μΐ of the
patient's serum was replaced by 200 μΐ normal human serum
and 20 μΐ phosphate buffered saline was replaced by 20 μΐ of
a diluted standard solution. The normal serum used in the pre-
paration of the standard curve was checked for CEA content
by reference to a "standard pool". For routine control, pooled
sera were prepared and aliquot s were stored at - 20°C.
In every assay run, four different pools covering the whole
range of measurable CEA values were incorporated. Statistical
evaluation was accomplished by calculating the mean value
for a period of several weeks and the 95 % confidence limits.
The results of assay routinely performed in one run were
accepted only if at least 3 out of 4 pools showed values within
'these limits.
Radioimm n -assay in urine (system 2)
Urine samples were dialysed against phosphate buffered saline
for 3 hours at 4°C while stirring, and stored frozen until assay.
The incubation tubes (plastic tubes; size 4 cm, i.d. 8 mm with
round bottom) contained 100 μΐ dialysed urine and 100 μΐ
antiserum diluted with phosphate buffered saline containing
rabbit serum. After overnight incubation at 37°C, 50 μΐ
labelled CEA solution (3 μg/l) were added. Incubation was
continued for 2 hours. The contents of the tubes were then
subjected to the procedure as described for the assay in serum.
For the construction of standard inhibition curves, aliquots
(100 μΐ) of diluted CEA solutions were used. Again, two
different stock solutions were used for the preparation of serial
dilutions in phosphate buffered saline containing rabbit serum.
For control a CEA solution in phosphate buffered saline con-
taining rabbit serum was prepared and aliquoted. Aliquots were
thawed and run with every series of routine samples. The inter-
assay variability of one control over a period of 6 months was
8:8% (mean 54 /ug'/l, η = 26).
Titration of antibody
As a control after each radio^iodination, antiserum was titrated
and the shape of the titration curve was estimated. The concen-
tration^iving about 75% of the maximal precipitation of radio-
activity was chosen.
For system 1, 50 μΐ portions of six dilutions (usually from 10"?
down to 3 Χ 10"5 in steps of 1:3) of antiserum were added to
0.2 ml human normal serum. Then, 50 μΐ of [12SIJCEA was
added. The reaction mixture was incubated for 3 hours at
37°C.
For system 2, tubes were used containing 100 μΐ diluted anti-
serum (in phosphate buffered saline containing rabbit serum),
100 μΐ phosphate buffered saline containing rabbit serum and
50 μΐ iodinated CEA (3 μg/l). The tubes were incubated for
2 hours at 37°C.
Separation of antibody-bound CEA from unbound CEA
This procedure was followed in system 1, system 2 and in
the titration of antibody; 50 μΐ normal goat serum at appro-
priate dilution (with phosphate buffered saline containing
rabbit serum) followed by 50 μΐ rabbit anti-^oat serum (usually
diluted with phosphate buffered saline containing rabbit serum)
were added. The tubes were stored overnight at 4°C.
After addition of 0.3 ml phosphate buffered saline centrifugation
was carried out. The supernatant was carefully removed by
aspiration. The residue and supernatant were then counted sepa-
rately. Quantitation of the appropriate dilution of the precipi-
tating antiserum and the normal goat serum with respect to the
applied dilution of the anti-CEA antiserum was achieved by a
checkerboard titration procedure.
Comments
Chemical characterization of2SDI
The amino acid and monosaccharide composition of the
CEA preparation is given in table 1.
Immunological characterization of2SDI by immuno-
diffusion
Figure 1 shows complete identity between 2SDI and a
reference CEA prepared by Dr. Searle (Charing Cross
Hospital, London). The anti-CEA antiserum applied in
Tab. 1. Amino-acid and carbohydrate composition of 2SDI.
For comparison, data on CEA prepared by Dr. Egan
(Duarte, California) are given.
Amino acid1) 2SDI CEADu
lysine
histidine
argin ine
aspartic acid
threonine
serine
glutamic acid
prpline
glycine
alanine
cysteine
valine
methionine
isoleucine
leucine
tyrosine
phenylalanine
monosaccharide2)
f u cose
mannose
galactose
N-acetyl-galaetosamine
N-acetyl-glucosamine
sialic acid
*) mole/ 100 mole
2)% by weight
2.1
1.6
3.4
14.8
8.7
10.3
10.8
7.8
5.7
5.7
2.1
6.9
0.1
3.9
8.7
4.8
2.5
7.2
7.2
10.0
0.6
16.7
2.6
2.8
1.7
3.1
15.7
8.7
11.4
9;6
8.0
6.3
6.2
1.6
6.6
0.4
3.7
7.6
4.2
2.2
9.2
9.3
8.9
1.7
15.7
variable
J. Clin. Chem. Clin. Biochem. / Vol. 14,1976 / No. 8 27*
380 Persijn and Korsten: R ad ioimmu no-assay for carcino-embryonic antigen in serum and urine
2SDI CEA
ACE
50
30
ο
•οΑ
10
I
1000 250 63
Cord no-embryonic antigen [^g/I]
Fig. 1. Comparative radial immunodiffusion. For explanation
see text (Magnification 4.4x).
Fig. 2. Comparison of standard inhibition curves (system 2)
obtained with doubling concentrations of CEAL (°—°)
and 2SDI (·--·). Antiserum: anti-CEA G-10-2, diluted
1/10 000.
the Ouchterlony plates was prepared by the Todd group
(Duarte, California) and named Ace 17 (27). A comple-
tely identical result was obtained with an unabsorbed
rabbit anti-CEA antiserum. No spur was observed in both
cases.
Immunological characterization of 2SDI and NKI-3
under radioimmunoassay conditions
In order to check the antigenic identity of 2SDI, other
preparations of CEA and anti-CEA antisera were com-
pared with the preparations used in assay system 1 or
assay system 2. For this purpose different standard inhi-
bition curves were prepared, in which unlabelled or
labelled CEA or anti-CEA antiserum was replaced by a
similar preparation kindly provided by other groups.
Standard inhibition curves obtained in system 2 by serial
dilutions of CEAL and dilutions of 2SDI were parallel
(fig. 2). Both experiments were performed using labelled
CEA from the Lausanne group.
Figure 3 compares a standard inhibition curve .(system 1)
with a standard curve obtained by serial dilution of CEA
prepared by Dr. Gold's group (Montreal). The other
reagents, such as labelled 2SDI, antiserum NKI-3 and
normal serum, were identical for both curves. A nearly
identical behaviour of 2SDI and the CEA from the
Montreal group is evident from this figure.
Figure 4 a shows the inhibitioa lines for 2SDI and CEA
supplied by TodcTs group (Duarte, California) in an
assay (system 2) based on the anti-CEA antiserum Ace.
In two out of three experiments labelled CEA was pre-
pared from 2SDI, in one experiment from CEA supplied
by Toad's group. It will be noted that the different
curves are superimposable except for the range above
5«
EJ3
530
I 20
10
ι I
100 50 25 12.5 6.2 3.1
Corcino-embryonic antigen
1.5 0.7
Fig. 3. Comparison of standard inhibition curves (system 1)
obtained with CEA prepared by Dr. Gold's group
(·—·) and 2SDI (o—o). Antiserum: anti-CEA NKI-3,
diluted 1/16 000.
32 /xg/1. A similar experiment, but based on the anti-CEA
antiserum NKI-3, is described in figure 4b. Replacement
of unlabelled and labelled 2SDI by the corresponding
reagents of Toad's group yields a practically identical
curve. - .
A study of the binding-inhibitory activity of non-
specific cross-reacting antigen in the radioimmuno-
assay of CEA was made as follows. A standard inhibition
curve was obtained as described under "Materials and
Methods" for the assay in seruin. In an otherwise iden-
tical experiment, .serial dilutions of 2SDI were replaced
by solutions of non-specific cross reacting antigen
kindly provided by Dr. Neville (London). The results
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Corcino-embryonic ontigen l/ig/l]
250 125 63
Fig. 4. Comparison of standard inhibition curves (system 2). Antisera: anti-CEA Ace, diluted 1/3200 (a), and anti-CEA NKI-3, diluted
1/21 000 (b).
(a) binding of CEADU and [12SI] 2SDI (o—o); CEADU and [125I] CEADU (D—a); 2SDI and [125I] 2SDI (·—·); (b) binding
of CEADu and [125I] CEADU (·—·); 2SDI and [125I] 2SDI (o—o).
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100 25 6.2
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Fig. 5. Inhibition of binding of labelled CEA ([125I] 2SDI) by
CEA (2SDI, 9-^·) or by non-specific cross reacting anti-
gen (c^—o) in system 1. Antiserum: anti-CEA NKI-3,
diluted 1/12 000. '"
12500
Lung extract i/ig/l]
3.200 800 200 ., 0
ΘΟΟ 200 50 12.5 3
Carcino-embryonic antigen (/ig/U
(fig. 5) show that non-specific cross reacting antigen does
not interfere in the assay. Identical results were obtained
in the absence of normal serum (non-specific cross
reacting antigen tested to 500 μ|/1). In the same way,
non-specific cross reacting antigen did not replace
labelled 2SDI bound to G-10-2. The specificity of NKI-3
was further tested by adding up to 12,800 ng perchloric
acid extract of normal lung in the assay. No significant
inhibition by perchloric acid-soluble glycoproteins was
found (fig. 6).
On the other hand, normal serum causes decreased
binding of labelled CEA, as demonstrated in figure 7.
Since the binding curves show non-parallelism, non-
specific proteins may be largely responsible for the
.decrease observed.
Fig. 6. inhibition of binding of labelled CEA ((12SIJ 2SDI) by
CEA (2SDI, ·—·) or by perchloric acid extract of normal
lung (o—o) in system 2. Antiserum: anti-CEA NKI-3,
diluted 1/30 000.
In another experiment, iodinated 2SDI was incubated
with several blood group antisera as described by
Holburn et al. (24). Saturated ammonium sulphate
was then added and the precipitate and supernatant
were counted to determine the percentage of bound
labelled 2SDI.
Precipitated nori-specifically bound [125I]CEA was
determined by adding buffer instead of antibody solu-
tions.
Whereas anti-CEA antiserum did bind 92.0% of the
labelled 2SDI and non-specifically bound 2SDI was
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8.8%, binding by anti-A or other anti-blood group
antibodies was in the range of 9.1—14.0%. These results
indicate no significant association with blood group
substances.
Storage of reagents
It was observed that antisera, if stored frozen (undiluted
or diluted), retain their original binding activity even
after two years of storage. The binding capacities of
frozen dried NKI-3 made up with twice distilled water
after storage for 2 years, were unchanged.
It has been reported (28) that CEA loses its potency to
compete with labelled CEA for the binding sites if stored
in the frozen dried state for some months. However,
a solution of 2SDI kept frozen for more than one year
and a solution freshly prepared from 2SDI, stored frozen
dried for the same period showed identical standard
inhibition curves.
Methodological validation
Delaying addition of the labelled CEA as one of the modi-
fications of the Egan procedure considerably improved
the sensitivity of the assay. An illustration is given in
figure 8. Overnight incubation for the formation of the
antibody complex was performed for practical reasons.
Similar results were obtained with NKI-3 and 2SDI.
The standard pool
The percentage of bound to total [125I]CEA (%B/T) was
determined for sera from several healthy controls (non-
smokers). At the same time a standard inhibition curve
with NKI-3 was prepared, but according to system 2,
thus omitting normal serum. The results were quantl·
tated using this standard curve. It is realized that the
CEA contents thus measured are overestimated but in a
reproducible way (see fig. 7). The normal serum showing
TOO
~ 80
60
1 40
tuJD
20-
Fig. 7. Comparison of standard inhibition curves obtained with
[125I] 2SDI in the presence of normal serum (·—·,
system 1) and in absence of normal serum (o—o, system 2).
Antiserum: anti-CEA NKI-3.
_L _L
25
J_
Carcino-embryonic antigen [jig/I] 16
Fig. 8. Comparison of standard inhibition curves obtained by
addition of labelled CEA ([125ί] 2SDI) to the assay
mixture (system 1) simultaneously with the other reagents
and incubation overnight (o—o) or according to the
procedure described in "Materials and Methods".
Antiserum: anti-CEA Ace, diluted 1/2700.
the lowest CEA level was regarded as "zero-serum" by
definition. Next, a pool serum (about 10 μg/l) was pre-
pared. After careful mixing the standard pool was ali-
quoted and stored at - 20°C. Aliquots of the standard
pool were analysed (system. 1) for CEA under various
conditions, i.e. using different batches of [12SI]CEA of
varying age (up to 3 weeks). The mean value was 8.9
jug/1 ± 0.6 (n = 24). For the standard pool a value of
9.0 μg/l was assessed. A fresh batch of normal serum
was accepted only if·, with the corresponding standard
inhibition curve, a value for the standard pool was
obtained which lay between 8.0 and 10.0 /zg/1. If a value
below 8 Mg/1 was found, the normal serum contained an
unacceptable amount of CEA.
Results
Assay in serum
With the value of 3 μg/l a fall of approximately 10% in
the percentage binding was achieved.
Therefore 3.0 Mg/1 value was used as the cut-off point in
most assays. For the ranges of 30-40,16-24^ 10-14
and 4-6 μg/l the coefficients of variation were 7.2,6.2,
8.2 and 12.1 % respectively.
Sera from 115 apparently healthy men and women were
found to contain less than 3.0 /φ/Ι. The youngest indivi-
dual was 18 years old and the oldest was 65.
Of the 115 controls* 35 admitted that they smoked
regularly (at least 10 cigarettes or 4 cigars per day). Out
J. Clin. Chem. Clin; Biqchem. / Vol. 14,1976 / No. 8
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of these 115 controls, 36 had blood group ORhEH, 12
had blood group ORhD-, 25 had blood group ARhD+,
6 had blood group ARhD-, 8 had blood group BRhD+
and one had blood group ABRhD+. The blood group of
the remaining 27 controls was unknown. Serum from
six other healthy persons contained 4.0 to 6.0 Mg/1. All
but one smoked regularly. This result prompted us to
establish the normal range in 49 healthy persons, qual-
ified as blood donors and regularly smoking 15 or more
cigarettes per day. The age of the smokers varied from
19 to 65 years with a mean value of 35. Of these 49
persons, 14 were taking oral contraceptives and 4
received medication (tranquillizers, etc.). The results
are given in table 2.
Two sera, obtained from healthy persons with a high
titre of blood group A, were also tested for CEA content.
The result was in both cases < 3 μ§/1. A group of random
sera of eighty-five patients suffering from malignant
diseases were analysed according to the Hamen technique
(29, 30).
Figure 9 compares the results obtained by the two
methods. The values between the limits of detection
gave the regression: y = 1.30 χ + 0.68, r = 0.8908.
A standard inhibition curve obtained with Hoffmann
LaRoche reagents and one obtained with the same
reagents but replacing CEA by 2SDI were completely
superimposable.
Assay in urine
Clinical studies first concerned patients with bladder
carcinoma. At that time the only anti-CEA antiserum
available to us was G-10-2, and this antiserum was
adopted as a routine.
A representative curve is shown in figure 10. Results
lower than 30 /zg/1 were not quantitated but expressed
at < 30 jig/1. In a series of 20 healthy persons (pre-
dominantly males) values not exceeding 30 μg/l were
found. Since problems arose when determining urinary
CEA levels in normal females, the normal range will
be dealt with in another communication (part 2
of this series).
Tab. 2. CEA levels in smokers aged 19-65 years, the figures
denote number of smokers.
Group
smoking habit since
0.2- 2 years
2 - 5 years
5 -10 years
10 -20 years
more than 20 years
Total no.
4
7
13
10
15
CEA
<3
4
6
10
8
6
titre (Mg/1)
3-6 6-9
0 0
!') °322) I )
22) 0
92) 0
>30
30
l 25
I 20
•οοι
ί 1*
CS)
01
χ>
δ ίο
<3
--4·-
31χΊ*
<25 5 10 15 20
CEA (Hansens method)
25 >25
Fig. 9. Comparison of serum CEA levels measured by our and
by the Hansen method.
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3) received antibiotics 5 weeks ago
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Fig. 10. Standard inhibition curve according to system 2, repre-
sentative of those obtained in our laboratory. Antiserum:
anti-CEA G-10-2, diluted 1/10 000.
For the ranges of 120-150, 90-120, 60-90 and 30-60
/xg/1 the coefficients of variation were 11.6, 7.5, 8.6
and 11.0% respectively.
A random series of urines (with CEA contents between
15 and 100 Mg/1) analysed and stored at - 20°C there-
after, were re-run about three months later. Results
found in both runs followed the equation Υ (first run)
= 0.9929x + 4.07; r = 0.9948. A comparable series run
about a year later showed Υ (first run) = 1.164x -
8.19; r ==0.92721.
Later, the antisera NKI-3 and 6-G.3 became available.
The latter was a gift from the Neville group (London)
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and, like NKI-3, showed a single precipitation line with
crude CEA after immunoelectrophoresis.
Seventy-eight urine samples were tested with G-10-2 and
6-G-3. Result: 54 samples had values below 25 /zg/1 with
both antisera. The other samples showed a reasonable
correlation (r = 0.8504). Samples re-run with NKI?3
showed a correlation in a range up to about 100 /zg/1
(figure 11).
At higher values, using NKI-3, dilution of the urine
(1:2) in a number of cases showed no parallelism to the
standard inhibition curve.
Table 3 compares values obtained in 12 samples with
and without preceding perchloric acid treatment for
15 minutes. Perchloric acid treatment was followed by
dialysis against twice distilled water and phosphate
buffer.
It will be noted that perchloric acid treatment reduced
the urinary CEA content in most cases. The presence
of tumour or urinary infection seemed to be of no
significance.
Discussion
Choice of assay
A survey of different systems for measuring CEA has
been given by Fleisher et al. (29). Disadvantages of the
zirconyl-gel assay (30), such as large sample volumes,
perchloric acid extraction of the samples and subsequent
immediate prolonged dialysis which requires large
volumes of carefully deionized water, led us to look for
less laborious procedures for measuring large series, the
direct assay according to a modified Egan procedure (15)
looked promising as such.
>240
ί
240
I
"
Ε 120
60
*o
ο ο
ο°Λ
ι
6α 120
Urinary CEA (with NKI-3) (jug/H
180
Fig. 11. Comparison of urinary CEA levels measured in un-
diluted (·) and 1:2 diluted (o) samples with anti-CEA
antiserum G-10^2 and with anti-CE antiserum NKI-3.
In the'indirect assay, the perchloric acid may alter the
immunochemical nature of CEA and thus the ability to
react with anti-CEA antisera. This is not a hypothetical
question in view of the results of our urinary CEA
measurements (tab. 3), which indicate that for such
measurements perchloric acid treatment should be
omitted. The data in figure 9 seem to indicate that per-
chloric acid treatment of sera does not influence the
test result, since the approximately 15% lower values
with the zirconyl-gel assay can be explained by endos-
Tab. 3. CEA levels (Mg/1) with and without preceding extraction (for 15 minutes) with 1 mol/1 perchloric acid (PCA)1).
antiserum
G-10-2
undiluted
Sample + PCA - PCA
1 - 42
2 66 140
3 160 260
4 - 235
5 106 113
6 66 138
7 88
8 68 210
9 130 290
10 - 93
11 ND2) 103
12 114 135
diluted 1:2
+ PCA - PCA
65
90 141
92
50
76
40
122
145
48
62 52
54 61
NKI-3
undiluted
+ PCA - PCA
31
75
>. loo ^ loo
84
80 63
87 '
68 68
83
> 100 > 100
72
104 · 89
66 82
diluted 1:2
+ PCA - PCA
<30
54
66 >100
70
- 36
53
39
59
70 88
ND2)
44
59
tumour
present
+
+
+
+
+
__
• —
+
+
+
+
+
urinary
infection
present
_
—
—
__
_
+
+
+
+
+
+
+
) Test results were multiplied by 2, accounting for two-fold increase of volume by adding perchloric acid. Results < 30 were not
multiplied and are therefore not inserted in the table.
2) ND = not determined.
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motic increase of volume during dialysis. No significance
should be attached to some discrepancies shown in
figure 9 since the large sample volume required for the
zirconyl-gel assay (5 ml) made it impossible to confirm
these by repeating the assay by either of the two methods.
On the other hand, in opting for either the direct or the
indirect assay it should be considered that the incidence
of false elevated values is not lower with assays based on
perchloric acid extraction than with direct assays (31).
Absorption ofanti-CEA antisera
Where most investigators used absorbed antisera (3,7,
21, 32, 33, 34, 35, 36) and judged the specificity of the
antiserum by gel diffusion techniques, we raise two
critical remarks:
a) The presence or absence of certain precipitation lines
after gel diffusion is not a completely valid criterion for
mono-specificity in the radioimmuno-assay of the anti-
serum tested. Conditions such0 as concentrations pre-
valent in the radioimmuno-assay are totally different
from those in gel diffusion.
Cross-reacting antibodies such as anti-non-specific cross
reacting antigen-antibodies may be present and visible
in immunodiffusion but diluted out in the radioimmuno-
assay system to such a degree that they have no effect
on the test results. In gel diffusion the immune complex,
if formed, may be too weak to become visible.
b) In view of the abundance and diversity of materials
used in absorbing-out (for a review see I.e. (35)), the
affinity of anti-CEA antibodies to CEA may very well
be decreased by non-specific interactions or by CEA
present in the materials.
Indications of such interaction can be found in refer-
ences 33 and 36 and in this study (fig. 7). We inten-
tionally did not absorb-out NKI-3 since neither anti-non-
specific cross reacting antigen antibodies in the anti-
serum nor blood group substances in 2SDI could be
detected under the conditions of the radioimmuno-assay
(fig. 6j precipitation experiments with blood group anti-
bodies and results with Α-rich sera).
Identification of2SDI
The amino-acid and carbohydrate analysis data on
2SDI (tab. 1) suggest that we are working with
chemically pure material. A more complex question
is whether 2SDI is immunologicaUy CEA or related to
CEA. Similar behaviour of two different CEA prepare
tions in their binding curves with the same antiserum
is not a proof of complete immunological identity but
can lead to the conclusion that both preparations have
some antigenic groupings in common. However, testing
several CEA preparations (see fig.'s 2-4) from different
laboratories in comparative experiments with 2SDI
can contribute to answering the above question. The
fact that identical shapes and identical or nearly identical
slopes of binding curves were obtained when comparing
2SDI with CEA from different groups,.leaves little doubt
that 2SDI possesses the same antigenic groups as these
four preparations. In addition, the superimposability of
the curves (except for fig. 2) implies that this common
immunological identity can be related to a weight basis
and consequently that we are working with essentially
the same antigen. Small antigenic differences may exist
but since there are no other criteria for defining CEA,
we conclude that 2SDI is real CEA. An indication of the
existence of an antigenic difference can be found in
figure 4 a, showing less complete inhibition of labelled
2SDI by higher concentrations of CEADu.
Relativity of CEA levels
Several factors which can cause false CEA levels and
which in our opinion have not received due attention
in the literature, will now be discussed. Purification of
CEA by column chromatography involves elution by
phosphate buffer followed by dialysis and lyophilisation
of the fractions which possess CEA activity.
It is of utmost importance that dialysis is continued
till complete removal of phosphate salts.
In the preparation of 2SDI, dialysis was therefore
continued until the sodium content of the dialysate
was consistently zero. CEA preparations with different
salt contents will yield parallel but not superimposable
curves in the case of immunological identity. This might
explain figure 2. Secondly, let us consider the problem
of the selection of normal sera.for the preparation of
the standard inhibition curve. A small percentage of
apparently healthy persons has elevated values, mostly
in the range of 3-10 Mg/1 (16, 32, 37-40). It is there-
fore of great importance to ensure that a normal serum
is applied with the lowest, if possible zero, CEA content
to avoid alterations in measured CEA levels due to
changes from one batch of normal serum to another.
The problem of varying results has been pointed out
by Kupchik et al. (35). We agree with these authors that
the use of a strict cut-off level of 2.5 jug/1 between normal
and elevated is no longer universally acceptable. We
believe we have solved this problem by introducing the
"standard pool" as described in "Comments". In this
approach the selected normal serum is defined by the
standard pool. This provides an accurate means of con-
sistently maintaining a zero base-line, which is a pre-
requisite for long-term follow-up studies. Distributions
of normal sera thus defined, and their incorporations
into different assay systems would facilitate comparison
of results from different laboratories. We feel that, as a
reference material, normal sera checked against a
standard pool are needed as much as reference CEA
preparations. Statements by laboratories that a value of,
say, 8 μg/l or higher in patients with colonic carcinoma
indicates a poor prognosis (41) have limited value for
J. Clin. Chem. Clin. Biochem. / Vol. 14,1976 / No. 8
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other institutes unless a comparative evaluation is made
by exchange of normal serum and standard pool. In this
connection we might mention another problem. Elevated
CEA levels have been found in 14 per cent of 110
chronic cigarette smokers (42) with a direct assay and in
19 per cent of 620 smokers using the zirconyl gel assay
(38). The assays take 5 and 2.5 jug/1 as the lower limit of
positivity, respectively. Smoking habits were not eluci·:
dated in these reports. Our results seem to indicate that
smoking habits rather than age are related to elevated
serum CEA levels. Assessment of limits of CEA levels
in healthy smokers again is meaningful to other labora-
tories only after exchange of normal serum and standard
pool. The concentration of the components of the anti-
body population directed against different antigenic
groups may change at increasing dilution of the anti-
serum to such an extent that some will begin to play
a minor role in the radioimmuno-assay. At widely
different dilutions, therefore, there is a possibility of
obtaining more or less different values for the same
samples. To minimize problems in this field we have
used, throughout, antisera at dilutions giving about
three-quarters of the maximum binding. A complex
situation may still arise when two different antisera
with comparable percentage of binding differ in their
distribution of antibodies. Let us consider the presence
of an antigen in the sample possessing a determinant
with a low affinity for some groups of the antibody
population. High concentrations will not result in com-
pletely decreased binding of the labelled antigen as
compared with the standard inhibition curve. Conse-
quently the antigen will be quantitated too low. The
diluted (e.g. 1:2) sample may give a value higher than
calculated and possibly close to the value of the un-
diluted sample. These influences can manifest them-
selves in the comparison of two antisera. We believe
that the discrepancy in urinary CEA levels measured
with NKI-3 and G-10-2 implies that NKI-3 has less anti-
bodies (or antibodies with less affinity) directed against
a determinant of urinary CEA present predominantly in
urine samples with large amounts of CEA (The 2SDI
preparation might bear this determinant as well). The
data suggest the possibility that urinary CEA is more
heterogeneous than colonic CEA. The sensitivity of
CEA in urine to perchloric acid treatment (tab. 3) and
work reported by Neville et al. (43) support this. The
question.arises as to which antiserum can be used in
follow-up studies of bladder carcinoma patients. The
most important point in the management of patients
is that the change from normal to moderately increased
levels, or vice versa, is identified. Each of the three anti-
sera tested can be effectively used for this purpose.
Neville et al. (43) have advocated the use of an anti-
serum raised against purified urinary CEA. As long as
such an antiserum is not available we must apply criteria
valid for antisera used in the radioimmuno-assay of CEA.
Dosing remarks
Problems concerning the antigenic specificity of CEA
and cross-reacting relatives remain unsolved. A com-
parative study as presented in this report is necessary
to establish whether a definite CEA preparation or anti-
CEA antiserum can be used in clinical studies.
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